GE HealthCare announces 510(k) submission for CleaRecon DL technology designed to improve image quality in the interventional suite with AI-based reconstruction
December 03 2024 - 8:00AM
Business Wire
- CleaRecon DL* is designed to improve cone-beam computed
tomography (CBCT) image quality by removing streaks and help
clinicians improve their confidence in image interpretation when
analyzing CBCT data
GE HealthCare (Nasdaq: GEHC) announced today the 510(k)
submission to the U.S. Food and Drug Administration for CleaRecon
DL, deep learning technology, designed to improve the quality of
cone-beam computed tomography (CBCT) images by bringing artificial
intelligence (AI)-based 3D reconstruction to the interventional
suite. This technology, which is pending 510(k) clearance, will be
demonstrated at the Radiological Society of North America’s (RSNA)
2024 Annual Meeting taking place from December 1-4 in Chicago.
As demand for minimally invasive procedures continues to grow,
GE HealthCare is committed to helping clinicians use image guidance
technologies to their full potential by removing barriers with the
goal of helping providers achieve better clinical and operational
outcomes.
To be available on Allia™ Image-Guided Solutions (IGS) Systems,
CleaRecon DL is designed to use AI-based reconstruction to improve
image quality by removing streaks without introducing additional
artifacts. It is also designed to improve CBCT analysis through
clear images. This technology aims to advance the company’s vision
to accelerate CBCT adoption in daily practice.
“GE HealthCare has been a leader in CBCT for more than two
decades - offering continued innovation through offerings such as
augmented guidance solutions designed to improve procedure
outcomes, as well as developing a wide-bore platform capable of
acquiring CBCT with obese patients, even with their arms down,”
said Arnaud Marie, General Manager, Global Intervention at GE
HealthCare. “Over the years, artifacts created in scans through
natural movement of the body and the distribution of contrast have
posed another significant challenge to clinicians when obtaining
CBCT images - posing a major barrier to adoption of CBCT
technology. We designed CleaRecon DL to address this challenge so
physicians and their patients can benefit from this advanced
imaging technology.”
In addition to CleaRecon DL, GE HealthCare is also introducing
OnWatch Predict, predictive monitoring of interventional
image-guided systems to provide enhanced service and increase
system availability for on-time diagnosis, invasive procedures and
treatments. Combining ongoing system diagnosis with user interface
monitoring, image chain health and X-ray generation, OnWatch
Predict is designed to forecast component failure, allowing
clinicians to schedule service before an issue occurs with the
system and limiting unplanned downtime.
For more information on GE HealthCare’s Allia IGS platform and
the company’s commitment to advancing the practice of image guided
therapy with artificial intelligence and digitization tools, visit
GE HealthCare Booth #7330, RSNA 2024 press kit, or the
RSNA 2024 events page.
*CleaRecon DL1,2 1) Designed to be used with Allia™ systems. 2)
CleaRecon DL is an option using deep learning in 3DXR. 510(k) and
CE mark pending. Not available for sale in US or EU.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Advanced Visualization Solutions,
Patient Care Solutions, and Pharmaceutical Diagnostics businesses
help improve patient care from diagnosis, to therapy, to
monitoring. We are a $19.6 billion business with approximately
51,000 colleagues working to create a world where healthcare has no
limits.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for
the latest news, or visit our website https://www.gehealthcare.com
for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203284278/en/
Julie Allison Senior Communications Manager (347) 327-0836
julie.allison@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Nov 2024 to Dec 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Dec 2023 to Dec 2024